Dr. Sreelatha Katari, MD

Dr. Katari practices at Saint Luke's Hospital of Kansas City in Kansas City, Missouri, part of BJC Health.

Dr. Katari's NPI, 1285073544, was assigned on June 20, 2013. Dr. Katari holds Missouri license MT203512.

Dr. Katari's primary practice is Saint Luke's Hospital of Kansas City, at 4401 Wornall Road, Kansas City, MO 64111 in Jackson County. The practice phone is (816) 932-2000.

Dr. Katari's primary practice is Saint Luke's Hospital of Kansas City in Kansas City, Missouri, part of BJC Health. Dr. Katari is also affiliated with Saint Luke's North Hospital-Barry Road. The medical group on file is Saint Luke's Medical Group. Dmand AI also links Dr. Katari to 3 more hospitals, 1 group practice or clinic and 1 therapy and rehab clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Katari practices, 7 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Katari's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dmand AI has Dr. Katari's licenses on file in 2 states: Missouri and Pennsylvania.

CMS data shows 712 Medicare services from Dr. Katari across 5 procedure codes in 2024, for 151 Medicare patients. Medicare paid $49,838 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 151 Medicare patients who saw Dr. Katari in 2024. The largest group is under 65, with 103 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 33% are also on Medicaid. Their average risk score is 5.09, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Katari's median patient age at 57, with 44% women.

In 2024, Dr. Katari wrote 2,989 Medicare Part D claims for 224 patients. 91% of them were for generic drugs. CMS names the drug for 2,674 of them, across 52 drugs with 11 or more claims each, at $138,786 in total drug cost. In 2023, CMS named 3,262 claims across 52 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Katari for performance year 2024, reported as part of a group. Dr. Katari accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Katari as offering telehealth.

Dmand AI links 6 papers to Dr. Katari, published from 2019 to 2024. 2020 was the busiest year, with 2. Dr. Katari has published most often in Am J Transplant. Dr. Katari's most frequent co-authors are Wisit Cheungpasitporn, MD, Napat Leeaphorn, MD and Michael A. Mao, MD.

CMS Open Payments shows 9 general payments to Dr. Katari from 8 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 100% of the total. Takeda Pharmaceuticals U.S.A., Inc. paid the most, $102.